Corman: Rescheduling cannabis is a responsible move for Pennsylvania’s patients

During my more than 20 years in the Pennsylvania General Assembly, I was guided by a fundamental principle: sound public policy must strike a careful balance between compassion and common sense. That principle was at the heart of our bipartisan effort to establish Pennsylvania’s medical cannabis program in 2016, a program built with careful oversight, accountability, and, most importantly, the goal of helping Pennsylvanians facing serious medical conditions.

Today, that same principle is why I support the federal effort to reschedule cannabis from a Schedule I to a Schedule III controlled substance. It’s time to modernize outdated federal classifications and bring them in line with the science, the policy landscape across the country, and the needs of patients in our state.

Under current federal law, cannabis is classified as a Schedule I drug, the same category as heroin and LSD, implying it has no accepted medical use and a high potential for abuse. That simply doesn’t reflect reality. Nearly 40 states, including Pennsylvania, have created tightly regulated medical cannabis programs backed by physicians, researchers, and patient advocates alike. The evidence of medical benefit is substantial, and the regulatory structures in place are working to protect both patients and public health.

Rescheduling cannabis to Schedule III, a category that includes widely prescribed medications like codeine-based pain relievers and certain hormonal therapies, would acknowledge its legitimate medical applications while improving access and oversight. It would open the door for enhanced research, streamline compliance for medical cannabis businesses, and bring federal law more closely in line with what we’ve already implemented at the state level.

Perhaps the most important outcome of rescheduling would be the ability to expand and accelerate medical research. Because cannabis remains a Schedule I substance, researchers face significant legal and logistical barriers when attempting to study its therapeutic effects. Moving it to Schedule III would make it easier to conduct clinical trials, improve dosage guidance, understand interactions with other medications, and ultimately provide better-informed care for patients.

There are also clear economic and operational benefits. Under the current federal tax code, specifically Section 280E, cannabis-related businesses are not permitted to deduct standard expenses like payroll, rent or insurance. These are legitimate businesses operating in accordance with state law, providing a vital health service, and yet they face an unfair financial burden. Rescheduling would correct this imbalance, helping providers invest more in patient care and quality control.

Moreover, rescheduling would reduce the legal confusion and administrative obstacles that patients, providers and caregivers currently face. Financial institutions are often hesitant to serve cannabis businesses due to the conflicting legal status, leading to unnecessary risks and inefficiencies. By bringing federal policy more closely into alignment with state law, we can improve transparency, enhance public safety, and ensure patients receive consistent, regulated access to care.

Pennsylvania’s medical marijuana program is proof that a compassionate, well-regulated approach can work. It has helped thousands of residents manage chronic pain, seizures, PTSD and other serious conditions, often after other treatments failed. We’ve shown that it’s possible to put patient health first while maintaining accountability and public safety.

Rescheduling cannabis won’t solve every challenge overnight, but it’s a meaningful step forward. It’s a chance to update an outdated federal policy, support scientific research, and improve the quality of care for patients who rely on medical cannabis every day. I hope our state’s delegation to Washington, D.C. support this effort as much as I do.

Now is the time for federal policy to catch up to where states like Pennsylvania already are. Let’s move forward, guided by science, compassion, and a commitment to better health outcomes for all.